News | February 25, 2026
FDA greenlights Biocon’s Liraglutide for chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India’s pharmaceutical sector stands at a pivotal inflection point
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
